Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. | Challenges of driving CD30-directed CAR-T cells to the clinic